As part of our ongoing aim to bring you reports of new developments, we have added a review of a recent study update on the QUAZAR AML-001 trial - Long-term survival with oral azacitidine for patients with acute myeloid leukaemia in first remission after chemotherapy.
Independent commentary for the review has been provided by Dr Shuh Tan, a haematologist at St. Vincent’s Hospital Melbourne where she is the clinical lead for acute leukaemia and myeloid diseases.
Please login below to download this issue (PDF)